Regulation of androgen receptor signaling in prostate cancer

Prostate cancer is a significant cause of morbidity and mortality worldwide. Normal prostate tissue is regulated by androgens, which activate the androgen receptor, a nuclear receptor transcription factor. Most prostate tumors retain androgen dependence, therefore, current therapies for advanced prostate cancer either reduce androgen levels or prevent binding to the androgen receptor. Despite this regimen, prostate cancer invariably progresses to a fatal, androgen-refractory state. Although these relapsed tumors are androgen independent, they are still dependent on the androgen receptor for their growth and survival. The focus of this review will be to highlight our current understanding of the mechanisms of androgen receptor activation in androgen-refractory prostate cancer. How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed.

[1]  Robert Tibshirani,et al.  Transcriptional programs activated by exposure of human prostate cancer cells to androgen , 2002, Genome Biology.

[2]  A. Bilancio,et al.  Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.

[3]  O. Hiort,et al.  The Molecular Basis of Androgen Insensitivity , 2001, Hormone Research in Paediatrics.

[4]  H. Klocker,et al.  Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. , 1996, Cancer detection and prevention.

[5]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[6]  Duane D. Miller,et al.  Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. , 2004, Journal of medicinal chemistry.

[7]  Wei Zhang,et al.  Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells , 2002, Oncogene.

[8]  A. Brinkmann,et al.  Antiandrogens: selective androgen receptor modulators , 2002, Molecular and Cellular Endocrinology.

[9]  M. Dowsett,et al.  Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[11]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[12]  I. Thompson,et al.  Prostate cancer chemoprevention: an overview of United States trials. , 2004, The Journal of urology.

[13]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Duane D. Miller,et al.  A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. , 2004, Journal of medicinal chemistry.

[15]  F. S. French,et al.  Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer* , 2004, Journal of Biological Chemistry.

[16]  R. Tjian,et al.  Transcriptional coactivator complexes. , 2001, Annual review of biochemistry.

[17]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[18]  M. Vihinen,et al.  Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer , 2002, Laboratory Investigation.

[19]  H. Klocker,et al.  Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[21]  L. Chung,et al.  Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. , 2002, Differentiation; research in biological diversity.

[22]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[23]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[24]  E. Brown,et al.  Identification and validation of novel androgen-regulated genes in prostate cancer. , 2004, Endocrinology.

[25]  B. Katzenellenbogen,et al.  Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity , 2001, Cell.

[26]  S. Fuqua,et al.  Androgen Receptor Acetylation Governs trans Activation and MEKK1-Induced Apoptosis without Affecting In Vitro Sumoylation and trans-Repression Function , 2002, Molecular and Cellular Biology.

[27]  W. Pratt,et al.  Steroid receptor interactions with heat shock protein and immunophilin chaperones. , 1997, Endocrine reviews.

[28]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[29]  Jian Hui Wu,et al.  The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.

[30]  D. Fuchs,et al.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.

[31]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[32]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[33]  Desok Kim,et al.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer. , 2003, The Journal of urology.

[34]  D. Lamb,et al.  Androgen receptors and their biology. , 2001, Vitamins and hormones.

[35]  S. Gambhir,et al.  Interrogating androgen receptor function in recurrent prostate cancer. , 2003, Cancer research.

[36]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[37]  Zhiyong Guo,et al.  Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells , 2004, Oncogene.

[38]  H. Klocker,et al.  Androgen receptors in prostate cancer. , 2003, Endocrine-related cancer.

[39]  H. Scher,et al.  Collocation of androgen receptor gene mutations in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[41]  S. Hanash,et al.  Identification of androgen‐regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis , 2001, Proteomics.

[42]  L. Ossowski,et al.  Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line , 2004, Oncogene.

[43]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[44]  Yves A Muller,et al.  Structure/function analyses of human sex hormone-binding globulin: effects of zinc on steroid-binding specificity , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[45]  P. Koivisto,et al.  Androgen Receptor Alterations in Prostate Cancer Relapsed during a Combined Androgen Blockade by Orchiectomy and Bicalutamide , 2001, Laboratory Investigation.

[46]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[47]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[48]  J. Trapman,et al.  Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). , 2004, The Biochemical journal.

[49]  M. Gleave,et al.  Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer , 2004 .

[50]  F. S. French,et al.  Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. , 1995, Molecular endocrinology.

[51]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[52]  A. Bilancio,et al.  Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action , 2003, The Journal of cell biology.

[53]  Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. , 2001, Molecular endocrinology.

[54]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[55]  D. Edwards,et al.  A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) , 1999, Molecular endocrinology.

[56]  E. Bissonette,et al.  Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.

[57]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[59]  D. Chopin,et al.  Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen‐independent growth in prostate cancer , 2004, International journal of cancer.

[60]  D. Tindall,et al.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.

[61]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[62]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  V. Jordan,et al.  Selective estrogen receptor modulation: concept and consequences in cancer. , 2004, Cancer cell.

[64]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[65]  G. Wise,et al.  Cytokine variations in patients with hormone treated prostate cancer. , 2000, The Journal of urology.

[66]  E. Gelmann,et al.  Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. , 2004, Molecular endocrinology.

[67]  G. Coetzee,et al.  Contribution of the Androgen Receptor to Prostate Cancer Predisposition and Progression , 2004, Cancer and Metastasis Reviews.

[68]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Heikki Lehväslaiho,et al.  The Androgen Receptor Gene Mutations Database , 1998, Nucleic Acids Res..

[70]  K. Burnstein,et al.  Two androgen response elements in the androgen receptor coding region are required for cell-specific up-regulation of receptor messenger RNA. , 1996, Molecular endocrinology.

[71]  P. Scardino,et al.  National Comprehensive Cancer Network guidelines for the management of prostate cancer. , 2003, Urology.

[72]  J. Moul,et al.  Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes , 2001, International journal of cancer.

[73]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[74]  G. Bartsch,et al.  Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth , 2002, Molecular and Cellular Endocrinology.

[75]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[76]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[77]  J. Palvimo,et al.  Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[78]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[79]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[80]  G. Buchanan,et al.  A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. , 2002, Molecular endocrinology.

[81]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[82]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[83]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[84]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[85]  V. Ogryzko,et al.  p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation* , 2000, The Journal of Biological Chemistry.

[86]  S. Oñate,et al.  Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway , 2003, Oncogene.

[87]  G. Murphy,et al.  Circulating levels of interleukin‐6 in patients with hormone refractory prostate cancer , 1999, The Prostate.

[88]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[89]  R. Schiff,et al.  Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[91]  P. Koivisto,et al.  Androgen Receptor Mutations in High-Grade Prostate Cancer before Hormonal Therapy , 2003, Laboratory Investigation.

[92]  Duane D. Miller,et al.  Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. , 2004, Endocrinology.

[93]  Duane D. Miller,et al.  Pharmacodynamics of Selective Androgen Receptor Modulators , 2003, Journal of Pharmacology and Experimental Therapeutics.

[94]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[95]  M. Almeida,et al.  Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. , 2003, The Journal of clinical investigation.

[96]  A. D. De Marzo,et al.  Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? , 2003, The Journal of clinical endocrinology and metabolism.